News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Bridgehead Pharmalicensing Group Has Today Announced That It Has Acquired 100% Of The Equity Of Healthcare Education Services Ltd From ML Laboratories PLC (LS:MLB)

10/19/2005 5:09:57 PM

MELTON MOWBRAY, England--(BUSINESS WIRE)--Feb. 6, 2004--Bridgehead Pharmalicensing Group Ltd has today announced that it has acquired 100% of the equity of Healthcare Education Services Ltd (Healthcare), from ML Laboratories plc.

As part of the integration of Healthcare, a new Group name, Bridgehead International Ltd, will be adopted.

Healthcare is based near London in the UK and supplies services to the international pharmaceutical and biotechnology sector, including some of the world's leading players, where it has achieved global preferred supplier status.

Healthcare services include:

Medical communications: communication strategy, publication planning, congresses and meetings, multi-media solutions and market ownership programmes.

Professional relations: opinion leader mapping, investigator meeting and advisory boards, speaker bureau and accredited physician education.

Medical education: open enrolment programmes, product-specific seminars, clinical experience programmes, e-media content and distance learning.

The three operating divisions of Bridgehead International Ltd will now comprise Healthcare, Pharmalicensing and Bridgehead Consulting. The change of name to Bridgehead International Ltd reflects the strong distribution of the group's client base across USA, Asian and European markets.

Bridgehead Corporate Development Director, David Alcraft, said:

"Healthcare will complement the Market Access and Pricing and Reimbursement advisory service, so successfully introduced last year by Bridgehead Consulting. Healthcare is already a strong business and one which we are sure will perform well under our ownership - especially as we leverage synergies across our combined services and client base. We have already proven this model following the Pharmalicensing merger 7 months ago.

Bridgehead CEO, Tim Fitzgerald, commented that:

"The acquisition further strengthens our move to offer high value proprietary services both internationally and across the pharmaceutical 'R&D to market' value chain. We remain certain that the market for specialised services to pharmaceutical companies is a very exciting place to be and, with our full time staff now approaching 40, we are one of the largest independent groups in our chosen market."

For further information, please see


Bridgehead Tim Fitzgerald, CEO or David Alcraft, Corporate Development Director +44 1664 503700

Read at

comments powered by Disqus